This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss
For any queries, please contact Customer Services or your Account Manager. Dismiss
News & Analysis (323)
-
February 26, 2026 | Insight IP licensing and business: Feb. 13-26
...Lilly & Co. to develop and commercialize CSL’s anti-interleukin-6 (IL-6) monoclonal antibody clazakizumab.Clazakizumab...
Sections: Intellectual Property
-
February 12, 2026 | Official Statement Eli Lilly, Ventyx Biosciences receive early termination from US FTC
Sections: DealRisk® and Mergers and Acquisitions
-
February 02, 2026 | Official Statement Lilly-Ventyx US premerger waiting period set to expire Feb. 23
Sections: DealRisk® and Mergers and Acquisitions
Get the inside track, with MLex
With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
TRY MLEX FREE FOR 14 DAYS
View full search results
Already a subscriber? Click here to login